Ajanta Pharma Limited (BOM:532331)
India
· Delayed Price · Currency is INR 2,933.75
-57.15 (-1.91%)
At close: Mar 9, 2026
Ajanta Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Net Income | - | 9,204 | 8,162 | 5,880 | 7,127 | 6,539 | Upgrade
|
| Depreciation & Amortization | - | 1,359 | 1,304 | 1,267 | 1,214 | 1,114 | Upgrade
|
| Other Amortization | - | 82.2 | 50.1 | 41 | 39.4 | 46.9 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 6 | -34.9 | 61.9 | 38.7 | 22.1 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | -113.1 | -20.1 | 14.8 | -52.3 | 51.9 | Upgrade
|
| Stock-Based Compensation | - | 38.8 | 54.9 | 2.2 | 3 | 0.2 | Upgrade
|
| Other Operating Activities | - | -793.7 | -667.1 | -14.1 | -748.2 | 76.8 | Upgrade
|
| Change in Accounts Receivable | - | 804.8 | -1,789 | -105.5 | -2,697 | 311.3 | Upgrade
|
| Change in Inventory | - | -745.1 | -123 | -223.7 | -256.6 | -2,715 | Upgrade
|
| Change in Accounts Payable | - | -84.5 | 408.5 | 969.1 | -480.2 | 111.5 | Upgrade
|
| Change in Other Net Operating Assets | - | 1,814 | 505.5 | 28.6 | 1,430 | 204.2 | Upgrade
|
| Operating Cash Flow | - | 11,572 | 7,851 | 7,921 | 5,617 | 5,763 | Upgrade
|
| Operating Cash Flow Growth | - | 47.41% | -0.89% | 41.02% | -2.53% | 26.17% | Upgrade
|
| Capital Expenditures | - | -3,179 | -1,524 | -1,745 | -1,488 | -1,716 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 11.4 | 133.8 | 7.3 | 183.8 | 17.1 | Upgrade
|
| Investment in Securities | - | -1,040 | 1,776 | -3,907 | 287.8 | -1,255 | Upgrade
|
| Other Investing Activities | - | 442.4 | 267.9 | 48.7 | 275.8 | 129.7 | Upgrade
|
| Investing Cash Flow | - | -3,765 | 653.9 | -5,596 | -741 | -2,824 | Upgrade
|
| Long-Term Debt Issued | - | 11 | 0.6 | - | 2.3 | - | Upgrade
|
| Total Debt Issued | - | 11 | 0.6 | - | 2.3 | - | Upgrade
|
| Long-Term Debt Repaid | - | -114.6 | -125.5 | -112.3 | -137.5 | -626 | Upgrade
|
| Total Debt Repaid | - | -114.6 | -125.5 | -112.3 | -137.5 | -626 | Upgrade
|
| Net Debt Issued (Repaid) | - | -103.6 | -124.9 | -112.3 | -135.2 | -626 | Upgrade
|
| Issuance of Common Stock | - | 0.1 | - | - | - | - | Upgrade
|
| Repurchase of Common Stock | - | -3,513 | -3,883 | - | -2,856 | -1,354 | Upgrade
|
| Common Dividends Paid | - | -3,494 | -6,422 | -896.9 | -822.1 | -829 | Upgrade
|
| Other Financing Activities | - | -223.5 | -81.3 | -72.8 | -783.9 | -373.8 | Upgrade
|
| Financing Cash Flow | - | -7,334 | -10,511 | -1,082 | -4,597 | -3,183 | Upgrade
|
| Net Cash Flow | - | 473 | -2,006 | 1,243 | 279 | -243.6 | Upgrade
|
| Free Cash Flow | - | 8,393 | 6,327 | 6,176 | 4,129 | 4,047 | Upgrade
|
| Free Cash Flow Growth | - | 32.66% | 2.44% | 49.59% | 2.02% | 86.20% | Upgrade
|
| Free Cash Flow Margin | - | 18.06% | 15.03% | 16.50% | 12.36% | 14.01% | Upgrade
|
| Free Cash Flow Per Share | - | 67.05 | 50.21 | 48.20 | 31.84 | 30.98 | Upgrade
|
| Cash Interest Paid | - | 207.4 | 72.1 | 58.4 | 102 | 49.6 | Upgrade
|
| Cash Income Tax Paid | - | 3,230 | 3,121 | 1,513 | 2,391 | 2,304 | Upgrade
|
| Levered Free Cash Flow | - | 6,621 | 1,165 | 8,146 | 1,893 | 3,096 | Upgrade
|
| Unlevered Free Cash Flow | - | 6,750 | 1,210 | 8,183 | 1,956 | 3,148 | Upgrade
|
| Change in Working Capital | - | 1,789 | -997.8 | 668.5 | -2,004 | -2,088 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.